1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. North America Gastrointestinal Drugs Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. North America Gastrointestinal Drugs Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. North America Gastrointestinal Drugs Market Regional Analysis
6.2 North America Gastrointestinal Drugs Market Revenue 2021-2031 (US$ Million)
6.3 North America Gastrointestinal Drugs Market Forecast Analysis
7. North America Gastrointestinal Drugs Market Analysis – by Drug Class
7.1 Biologics
- 7.1.1 Overview
- 7.1.2 Biologics: North America Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.2 Antidiarrheal and Laxatives
- 7.2.1 Overview
- 7.2.2 Antidiarrheal and Laxatives: North America Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.3 Acid Neutralizers
- 7.3.1 Overview
- 7.3.2 Acid Neutralizers: North America Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.4 Anti-inflammatory Drugs
- 7.4.1 Overview
- 7.4.2 Anti-inflammatory Drugs: North America Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.5 Antiemetic and Antinauseants
- 7.5.1 Overview
- 7.5.2 Antiemetic and Antinauseants: North America Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.6 Others
- 7.6.1 Overview
- 7.6.2 Others: North America Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
8. North America Gastrointestinal Drugs Market Analysis – by Application
8.1 Irritable Bowel Syndrome
- 8.1.1 Overview
- 8.1.2 Irritable Bowel Syndrome: North America Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.2 Inflammatory Ulcerative Colitis
- 8.2.1 Overview
- 8.2.2 Inflammatory Ulcerative Colitis: North America Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.3 Crohn\'s Disease
- 8.3.1 Overview
- 8.3.2 Crohn\'s Disease: North America Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.4 Gastroenteritis
- 8.4.1 Overview
- 8.4.2 Gastroenteritis: North America Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.5 Celiac Disease
- 8.5.1 Overview
- 8.5.2 Celiac Disease: North America Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.6 Others
- 8.6.1 Overview
- 8.6.2 Others: North America Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
9. North America Gastrointestinal Drugs Market Analysis – by Route Of Administration
9.1 Oral
- 9.1.1 Overview
- 9.1.2 Oral: North America Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
9.2 Parenteral
- 9.2.1 Overview
- 9.2.2 Parenteral: North America Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
10. North America Gastrointestinal Drugs Market Analysis – by Distribution Channel
10.1 Hospital Pharmacies
- 10.1.1 Overview
- 10.1.2 Hospital Pharmacies: North America Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
10.2 Retail Pharmacies
- 10.2.1 Overview
- 10.2.2 Retail Pharmacies: North America Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
10.3 Online Pharmacies
- 10.3.1 Overview
- 10.3.2 Online Pharmacies: North America Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
11. North America Gastrointestinal Drugs Market – North America Analysis
11.1 Overview
11.2 North America
- 11.2.1 North America Gastrointestinal Drugs Market Breakdown, by Key
Country, 2024 and 2031 (%)
- 11.2.1.1 North America Gastrointestinal Drugs Market – Revenue and
Forecast Analysis – by Country
- 11.2.1.1 US:
North America Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.1.1 US: North America Gastrointestinal Drugs Market Breakdown, by Drug Class
- 11.2.1.1.2 US: North America Gastrointestinal Drugs Market Breakdown, by Application
- 11.2.1.1.3 US: North America Gastrointestinal Drugs Market Breakdown, by Route Of Administration
- 11.2.1.1.4 US: North America Gastrointestinal Drugs Market Breakdown, by Distribution Channel
- 11.2.1.2 Canada:
North America Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.2.1 Canada: North America Gastrointestinal Drugs Market Breakdown, by Drug Class
- 11.2.1.2.2 Canada: North America Gastrointestinal Drugs Market Breakdown, by Application
- 11.2.1.2.3 Canada: North America Gastrointestinal Drugs Market Breakdown, by Route Of Administration
- 11.2.1.2.4 Canada: North America Gastrointestinal Drugs Market Breakdown, by Distribution Channel
- 11.2.1.3 Mexico:
North America Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.3.1 Mexico: North America Gastrointestinal Drugs Market Breakdown, by Drug Class
- 11.2.1.3.2 Mexico: North America Gastrointestinal Drugs Market Breakdown, by Application
- 11.2.1.3.3 Mexico: North America Gastrointestinal Drugs Market Breakdown, by Route Of Administration
- 11.2.1.3.4 Mexico: North America Gastrointestinal Drugs Market Breakdown, by Distribution Channel
12. Competitive Landscape
12.1 Heat Map Analysis
12.2 Company Positioning and Concentration
13. Industry Landscape
13.1 Overview
13.2 Market Initiative
13.3 Partnerships and Collaborations
13.4 Other Developments
14. Company Profiles
14.1 Sanofi SA
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 GSK Plc
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 Johnson & Johnson
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 Bausch Health Companies Inc
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 AstraZeneca Plc
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 Takeda Pharmaceutical Co Ltd
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 AbbVie Inc
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 Bayer AG
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 Celltrion Inc
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments
14.10 Pfizer Inc
- 14.10.1 Key Facts
- 14.10.2 Business Description
- 14.10.3 Products and Services
- 14.10.4 Financial Overview
- 14.10.5 SWOT Analysis
- 14.10.6 Key Developments
15. Appendix
15.1 About Business Market Insights
15.2 List of Abbreviations